Impact of the COVID-19 pandemic on the hospital attendance of patients with primary cervical cancer in Heilongjiang,China

Information regarding the impact of the coronavirus disease 2019 (COVID-19) pandemic on cervical cancer in mainland China is lacking. We explored its impact on the hospital attendance of patients with primary cervical cancer. We included 1918 patients with primary cervical cancer who initially attended Harbin Medical University Cancer Hospital between January 23, 2019, and January 23, 2021. Attendance decreased by 31%, from 1135 in 2019 to 783 in 2020, mainly from January to June (𝜒² = 73.362, P < .001). The percentage of patients detected by screening decreased from 12.1% in January-June 2019 to 5.8% in January-June 2020 (𝜒² = 7.187, P = .007). Patients with stage I accounted for 28.4% in 2020 significantly lower than 36.6% in 2019 (𝜒² = 14.085, P < .001), and patients with stage III accounted for 27.1% in 2020 significantly higher than 20.5% in 2019 (𝜒² = 11.145, P < .001). Waiting time for treatment was extended from 8 days (median) in January-June and July-December 2019 to 16 days in January-June (𝜒² = 74.674, P < .001) and 12 days in July-December 2020 (𝜒² = 37.916, P < .001). Of the 179 patients who delayed treatment, 164 (91.6%) were for the reasons of the healthcare providers. Compared to 2019, the number of patients in Harbin or non-Harbin in Heilongjiang Province and outside the province decreased, and cross-regional medical treatment has been hindered. The COVID-19 pandemic has negatively impacted cervical cancer patient attendance at the initial phase. These results are solid evidence that a strategy and mechanism for the effective attendance of cervical cancer patients in response to public health emergencies is urgently needed.     

PDCA在优化医院新冠病毒核酸检测流程中的应用

目的：应用PDCA循环优化医院新冠病毒核酸检测的流程，提升核酸检测能力，以满足疫情防控和临床患者的需求。方法：应用PDCA循环，分析核酸检测流程存在的问题，建立标准化的核酸检测体系。同时，收集2020年10月至12月（优化前）和2021年10月至12月（优化后）的数据，采用SPSS 22.0软件进行统计分析，以评价PDCA循环的优化效果。结果：经过PDCA循环优化后，总检测中位标本数从20 307个增加至71 403个，优化前后差异有统计学意义（P=0.018）。中位送检时间从224分钟缩短至208分钟，中位检测时间从234分钟缩短至151分钟，中位报告时间从461分钟缩短至371分钟，优化前后差异均有统计学意义（P < 0.001）。结论：应用PDCA循环，能够制定并持续完善标准化的核酸检测流程，有助于提高核酸检测能力和服务水平。     

菊花总黄酮含药血清对干眼细胞模型AR、NF-κB磷酸化蛋白及TGF-β1表达的影响＊

目的 观察菊花总黄酮在体外条件下对泪腺上皮细胞中雄激素受体（Androgen Receptor，AR）的调控作用及对下游的核因子κB（Nuclear Factor kappa B，NF-κB）、转化生长因子-β1（transforming growth factor-beta1，TGF-β1）的表达影响。方法 以过氧化氢（H₂O₂）诱导泪腺上皮细胞凋亡，建立细胞模型，设立无雄激素培养空白对照组、含雄激素培养对照组、无雄激素培养黄酮治疗组。以MTT法摸索含药血清最佳干预加入量；免疫印迹实验（Western Blot）以及实时荧光定量PCR法（Quantitative Real-Time PCR，qPCR）检测泪腺上皮细胞中AR、NF-κB及TGF-β1的表达情况；并应用雄激素受体阻断剂氟他胺进行AR阻断后再次检测上述指标 。结果 MTT法检测后计算得出含药血清干预细胞的最终浓度为13.2%；无雄激素培养黄酮治疗组及含雄激素培养对照组中AR、NF-κB及TGF-β1的表达增强，与空白对照组对比有显著差异（P<0.01）；无雄激素培养黄酮治疗组中NF-κB表达量比含雄激素培养对照组表达量低，两者间的差异有统计学意义。氟他胺及含药血清干预后，无雄激素培养黄酮治疗组及含雄激素培养对照组中AR及NF-κB的表达未见提高，无统计学意义。结论 菊花总黄酮对泪腺上皮细胞可能存在拟雄激素效应，从而使AR、NF-κB表达增加，并通过上调TGF-β1的表达，可能起到在泪腺局部的抗炎作用。     

腹部超声联合阴道灌注0.9%氯化钠诊断幼女阴道异物的临床价值

目的 分析腹部超声联合阴道灌注0.9%氯化钠对幼女阴道异物的诊断价值。方法 回顾性分析2018年1月—2021年12月就诊于赣州市妇幼保健院妇科的102例疑似阴道异物幼女临床资料。患儿均接受经腹部超声、阴道灌注0.9%氯化钠检查。以宫腔镜诊治结果作为金标准，分析经腹部超声单独检测或腹部超声联合阴道灌注0.9%氯化钠诊断阴道异物的准确性、有效性。结果 宫腔镜结果显示，患儿中阴道炎有21例（20.59%），阴道异物有81例（79.42%），其中棉絮状物、谷物、头发丝等线状物最为常见；单独诊断、联合诊断出阴道异物分别有69例和79例，与宫腔镜诊断结果的K值分别为0.689和0.897。将宫腔镜诊断结果作为金标准，单独诊断、联合诊断阴道异物的敏感性分别为0.765（95% CI：0.594，0.816）、0.951（95% CI：0.826，0.995），特异性分别为0.667（95% CI：0.563，0.786）、0.905（95% CI：0.795，0.972），准确度分别为0.745（95% CI：0.586，0.813）、0.941（95% CI：0.817，0.984），单独诊断、联合诊断的敏感性、特异性、准确度可信区间无重叠，说明有统计学意义。结论 阴道灌注0.9%氯化钠可增强幼女阴道异物在超声下的显影，提升诊断准确性、有效性，且操作简单、损伤小，起到清洁阴道作用。     

发达国家医学生器官捐献意愿研究现状的范围综述

目的了解发达国家医学生器官捐献意愿研究的目的、结果、障碍因素和解决对策。 方法以主题词和自由词联合的方式对PubMed、Web of Science、Ovid MEDLINE、Ovid EMBASE(Excerpta Medica)、EBSCOhost Complete和Cochrane Library等已发表文献数据库，以及灰色文献数据库York Centre for Reviews and Dissemination、Open Grey、ProQuest Dissertation and Theses和Mednar进行系统、全面地检索，并采用Arksey和O′Malley提出的范围综述框架进行文献资料整合。 结果共纳入17项发达国家医学生器官捐献意愿研究。研究背景主要为医学生未来对于公众器官捐献有着重要影响。研究结果表明，大多数医学生器官捐献意愿性良好，但不同亚组的研究结果不一；其最主要的障碍因素为医学生器官捐献相关知识的缺乏；解决对策主要为施予系统化、结构化和可评价的教育课程。 结论21世纪以来发达国家医学生器官捐献意愿研究方兴未艾，其研究的多层面、多角度以及揭示的问题、寻求的解决对策，可对我国现阶段医学生器官捐献的研究提供一定参考。     

Go-Ichi-Ni-San 2: A potential biomarker and therapeutic target in human cancers

Cancer incidence and mortality are increasing globally, leading to its rising status as a leading cause of death. The Go-Ichi-Ni-San (GINS) complex plays a crucial role in DNA replication and the cell cycle. The GINS complex consists of four subunits encoded by the GINS1, GINS2, GINS3, and GINS4 genes. Recent findings have shown that GINS2 expression is upregulated in many diseases, particularly tumors. For example, increased GINS2 expression has been found in cervical cancer, gastric adenocarcinoma, glioma, non-small cell lung cancer, and pancreatic cancer. It correlates with the clinicopathological characteristics of the tumors. In addition, high GINS2 expression plays a pro-carcinogenic role in tumor development by promoting tumor cell proliferation and migration, inhibiting tumor cell apoptosis, and blocking the cell cycle. This review describes the upregulation of GINS2 expression in most human tumors and the pathway of GINS2 in tumor development. GINS2 may serve as a new marker for tumor diagnosis and a new biological target for therapy.